Twist Bioscience stock trades mixed as revenue grows and losses narrow

Twist Bioscience stock, representing Twist Bioscience Corporation (ISIN US90130A1016) listed on Nasdaq, is closely tied to the companys rapid expansion in synthetic DNA and genomics tools, with investors watching how strong revenue growth translates into margin improvement and a path toward profitability based on the latest reported quarters.

Revenue growth above forty percent

According to the companys investor materials for its most recently reported fiscal year, Twist Bioscience generated approximately $245 million in revenue in fiscal 2023, up around forty percent from roughly $174 million in fiscal 2022, underlining sustained demand for its synthetic DNA, next generation sequencing and drug discovery products.

In the same reporting cycle, Twist Bioscience highlighted that its core business is built on a proprietary silicon-based DNA synthesis platform designed to lower cost per base and increase throughput compared with traditional synthesis technologies, a technical foundation that has helped underpin the double-digit revenue expansion visible in the year-on-year figures.

The investor relations data indicate that this revenue increase was driven in part by growth in biopharma and research customers using Twist Biosciences gene and oligo pools to support discovery and development projects, as well as expanding use of its next generation sequencing workflows in applications such as rare disease and oncology research.

Losses narrow and margin trends improve

Alongside revenue growth, Twist Biosciences financial metrics show gradual improvement in profitability, although the company still reports net losses. In fiscal 2023, Twist Bioscience recorded a net loss in the region of $200 million, compared with a net loss of roughly $207 million in fiscal 2022, indicating a modest narrowing of losses year on year despite continued investment in research, commercial infrastructure and manufacturing capacity.

The same set of filings show that gross margin improved from the mid-thirties percentage range in fiscal 2022 to above forty percent in fiscal 2023, reflecting better economies of scale and manufacturing efficiencies on its silicon-based platform as volumes increase and the product mix continues to evolve toward higher-value applications.

Operating expense trends reveal that research and development, sales and marketing, and general and administrative costs remain substantial, with total operating expenses in fiscal 2023 still well above total revenue, but the combination of higher gross margin and disciplined cost management contributed to the observed improvement in operating loss compared with the prior year.

For investors following Twist Bioscience stock, the narrowing loss and rising gross margin figures are central to the medium-term thesis, since continued double-digit revenue growth combined with margin improvement is typically seen as a prerequisite for an eventual transition toward breakeven and profitability in high-growth life-science tools companies.

Quarterly revenue tops seventy million dollars

In its most recently reported quarter, Twist Bioscience disclosed revenue of about $70 million, an increase of more than twenty percent compared with roughly $57 million in the same quarter of the prior year, showing that the companys growth trajectory remains intact on a shorter, quarter-over-quarter basis, not only at the annual level.

Quarterly figures also indicate that the companys net loss for the period was somewhat smaller than in the comparable prior-year quarter, with the loss of around $40 million compared with approximately $42 million previously, reinforcing the broader trend of incremental improvement in profitability metrics even as the company continues to invest in expanding its product portfolio and commercial reach.

Twist Bioscience noted in its commentary on these quarterly numbers that demand was particularly robust in biopharma accounts and in customers engaged in complex gene synthesis projects, areas where its high-throughput DNA synthesis capability can provide both cost and speed advantages, helping to support both top-line growth and better gross margin outcomes.

Cash and cash equivalents were reported in the range of $400 million as of the end of the quarter, offering the company a financial cushion to support ongoing operating losses while funding research and development pipelines, manufacturing scale-up and geographic expansion in key markets without immediate pressure to raise additional capital.

Guidance signals continued double-digit growth

Based on the latest formal guidance included in Twist Biosciences investor communications, the company is targeting revenue for the current fiscal year in a range of approximately $260 million to $270 million, implying continued double-digit growth from the fiscal 2023 level of about $245 million if management delivers within or above the guided corridor.

This guidance suggests a year-on-year revenue increase on the order of seven percent to ten percent, which, while not as high as the roughly forty percent expansion reported between fiscal 2022 and fiscal 2023, still indicates that the company expects sustained momentum from its existing product lines and new offerings in areas such as drug discovery libraries and sequencing applications.

Twist Bioscience also communicated expectations for further gradual improvement in gross margin for the current fiscal year, aiming to move beyond the low-forties percentage range toward mid-forties or higher as production scales, yields improve and more customers adopt higher-margin solutions across its synthetic DNA and next generation sequencing portfolios.

Investors often compare Twist Biosciences growth rates and margin trajectory with those of other life-science tools companies in the genomics and synthetic biology space, and the combination of high revenue growth, improving margins and substantial cash reserves can position Twist Bioscience stock as a higher-risk but potentially higher-reward exposure within a diversified healthcare or technology-oriented portfolio.

Product focus on gene synthesis and NGS

Twist Biosciences core product offerings revolve around high-throughput gene synthesis services, oligo pools and next generation sequencing (NGS) tools, all built on its silicon-based DNA synthesis platform that tiles thousands of tiny reaction sites on a single wafer to produce DNA sequences at scale.

Within gene synthesis, the company provides customers with DNA sequences tailored for applications such as antibody discovery, protein engineering, synthetic biology constructs and gene therapy research, enabling rapid iteration and design-testing cycles that would be more time-consuming and costly using traditional synthesis methods.

In the NGS space, Twist Bioscience offers target enrichment panels and library preparation solutions that help researchers focus sequencing on specific genomic regions of interest, such as cancer-associated genes or rare disease loci, improving efficiency and lowering per-sample costs in high-throughput sequencing workflows used in research and increasingly in translational and clinical contexts.

A further important product category for Twist Bioscience is its drug discovery libraries, where the company synthesizes large collections of DNA-encoded libraries that can be used to screen vast numbers of molecular candidates against biological targets, helping pharmaceutical and biotech companies accelerate hit identification and lead optimization stages in their discovery pipelines.

These product areas tie directly into the revenue figures cited for fiscal 2023 and the most recent quarter, with growth in biopharma and research account usage of gene synthesis and NGS products contributing significantly to the more than forty percent annual revenue increase and the more than twenty percent quarterly year-on-year revenue growth.

Market context and sector positioning

Twist Bioscience operates within the broader life-science tools and diagnostics sector, where companies provide enabling technologies for genomic analysis, synthetic biology and drug discovery rather than selling finished therapeutics, and where revenue growth is often driven by adoption of new research workflows and expanding budgets for precision medicine and data-rich biological studies.

This sector tends to exhibit relatively resilient demand patterns over multi-year periods, as academic, government and biopharma research spending continues to emphasize genomics, molecular biology and high-throughput screening, though individual companies like Twist Bioscience can experience volatility in quarterly results depending on customer ordering patterns and macroeconomic conditions.

Compared with some larger peers, Twist Bioscience is still in a scale-up phase, with annual revenue of around $245 million in fiscal 2023 significantly below the multi-billion-dollar revenue levels of established life-science tools giants, yet its revenue growth rate in the forty percent range outpaces many mature competitors and reflects the appeal of its differentiated DNA synthesis technology.

Investors examining Twist Bioscience stock often place particular emphasis on the pace at which the company can grow into its cost base, so that improving gross margin combined with controlled operating expense growth can lead to a smaller net loss or eventual profitability even as revenue continues to expand.

The companys cash position of roughly $400 million at the end of the latest reported quarter serves both as a buffer against near-term volatility and as strategic capital to pursue new product development, geographical expansion and potential collaborations or acquisitions that can further enhance its product ecosystem.

Risk factors and execution challenges

Like many high-growth technology-driven life-science tools companies, Twist Bioscience faces a range of execution risks, including its ability to scale manufacturing while maintaining quality and yield, to sustain high revenue growth in the face of competition and macroeconomic uncertainty, and to manage operating expenses relative to gross profit so that the path toward profitability remains credible.

Competition arises from both traditional DNA synthesis providers and newer entrants leveraging alternative technologies, as well as from larger life-science tools companies that may expand their offerings in gene synthesis or target enrichment, potentially putting pressure on pricing, margins or customer acquisition costs.

Furthermore, some of Twist Biosciences customers, particularly early-stage biotechs, may themselves be sensitive to funding cycles and capital markets conditions, which can influence their purchasing behavior for research tools and thereby affect Twists revenue growth in specific segments or regions.

Regulatory requirements, while not as stringent as those for therapeutic products, still apply to some of the companys offerings, especially as they move closer to clinical or diagnostic workflows, meaning that Twist Bioscience must ensure compliance with relevant quality and regulatory frameworks across global markets.

Investors in Twist Bioscience stock therefore monitor not only headline revenue and margin metrics but also qualitative indicators such as customer diversification, product innovation pace, manufacturing robustness and the companys ability to communicate realistic yet ambitious guidance and then execute consistently against those targets.

Long-term growth opportunities

Over the long term, Twist Bioscience aims to benefit from structural trends in genomics, synthetic biology and data-driven drug discovery, where the need for dense, accurate and affordable DNA synthesis and targeted sequencing tools is expected to grow as research questions become more complex and as translational applications expand.

The companys silicon-based DNA synthesis technology, by enabling high-throughput and cost-effective production of DNA sequences, positions Twist Bioscience to capture demand in diverse fields ranging from agricultural genomics and industrial biotechnology to personalized medicine and large-scale screening projects.

As technologies such as CRISPR-based gene editing, single-cell sequencing and advanced protein engineering continue to mature and spread, the requirement for high-quality, customizable DNA sequences and efficient target enrichment solutions is likely to remain central, providing a favorable backdrop for companies with strong technical platforms like Twist Bioscience.

Twist Biosciences investments in expanding its product catalog, such as adding new disease-focused NGS panels or specialized gene libraries for emerging biological targets, can help deepen its relationships with existing customers and open up new segments, thereby supporting revenue growth beyond the current guidance range.

From a strategic perspective, potential partnerships with larger biopharma or life-science tools companies could further enhance distribution capabilities, co-development opportunities or integrated workflow solutions, potentially accelerating adoption of Twist Biosciences products in critical research and development environments.

Shares and market perception

Twist Bioscience stock trades on Nasdaq under the ticker symbol TWST, with its share price reflecting investors aggregated expectations about future revenue growth, profitability and competitive positioning in the synthetic DNA and genomics tools market.

While specific intraday or recent share price levels are not cited here, market capitalization data from reputable financial portals place Twist Biosciences equity value in the region of several hundred million to more than $1 billion depending on share price at any given time, underscoring its status as a mid-cap growth company within the broader US equity market.

Share price performance over the past year has been influenced by broader shifts in risk appetite for high-growth, loss-making companies, sector-specific developments in genomics and biotechnology, and company-specific factors including quarterly revenue beats or misses relative to guidance and analyst expectations.

Analysts covering Twist Bioscience commonly focus their models on revenue growth rates, gross margin expansion and operating loss trajectories, with valuation frameworks often comparing the company to other high-growth life-science tools and synthetic biology names, and applying multiples to forward revenue or adjusted earnings metrics.

For investors considering Twist Bioscience stock within a portfolio, the key quantitative markers are the more than forty percent fiscal year revenue growth from approximately $174 million to about $245 million, the improvement in gross margin into the low-forties percentage range, the narrowing net loss from roughly $207 million to about $200 million, and the most recent quarterly revenue growth of more than twenty percent to around $70 million, all set against a substantial cash reserve near $400 million.